№ lp_1_2_59498
File format: docx Character count: 100821 File size: 116 KB
This document is a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding the listing of nivolumab (Opdivo®) and its combination with ipilimumab (Yervoy®) for the treatment of unresectable melanoma with BRAF V600 mutation.
Year: 2023
Region / City: Australia
Subject: Cancer Treatment / Immunotherapy
Document Type: Submission
Organ / Institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Bristol-Myers Squibb
Target Audience: Medical professionals, healthcare policy makers, pharmaceutical industry stakeholders
Period of Validity: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Notification to the Parties No. 707 Concerning the Regulation of Exportation of CITES Specimens in Egypt, December 1992
Year: 1992
Region / City: Egypt, Lausanne
Subject: Wildlife export regulations
Document Type: Official notification
Issuing Authority: CITES Secretariat
Author: Management Authority of Egypt
Target Audience: Parties to CITES
Period of Enforcement: 1 October 1992 – 1 April 1993
Date of Issue: 21 December 1992
Referenced Documents: Notification to the Parties No. 662, 16 January 1992
Species Mentioned: Allactaga tetradactyla, Canis aureus lupaster, Dugong dugon, Equus (Asinus) asinus africanus, Fennecus zerda, Herpestes ichneumon, Hystrix cristata, Proteles cristatus, Spalax micropthalmus, Vulpes rueppelli, Vulpes vulpes, Walterinnesia aegyptia
Obeticholic acid for the treatment of primary biliary cholangitis: cost-effectiveness of combination therapy with ursodeoxycholic acid and monotherapy
Year: 2023
Region / city: Australia
Subject: Pharmaceutical treatment for primary biliary cholangitis
Document type: Authority submission for PBS listing
Organization: Emerge Health Pty Ltd
Author: Emerge Health Pty Ltd
Target audience: Healthcare professionals, gastroenterologists, hepatologists, prescribers
Period of validity: Ongoing
Approval date: Not specified
Date of changes: Not specified
NIVOLUMAB, Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®IPILIMUMAB Injection concentrate for I.V. infusion 50 mg in 10 mL Yervoy®
Year: 2024
Region / City: Australia
Subject: Nivolumab and ipilimumab treatment for unresectable malignant mesothelioma
Document type: Submission report
Organ / Institution: PBAC, DUSC, TGA
Author: Unknown
Target audience: Pharmaceutical regulators, healthcare professionals
Period of validity: 2021-2024
Approval date: July 2021
Date of changes: March 2024
NIVOLUMAB plus IPILIMUMAB, NIVOLUMAB: Injection concentrate for I.V. infusion 100 mg in 10 mL, Injection concentrate for I.V. infusion 40 mg in 4 mL, OPDIVO®; IPILIMUMAB: Injection concentrate for I.V. infusion 200 mg in 40 mL, Injection concentrate for I.V. infusion 50 mg in 10 mL, YERVOY®; Bristol-Myers Squibb Australia Pty Ltd
Year: 2022
Region / City: Australia
Theme: Oncology, Medical Treatment
Document Type: Pharmaceutical Submission
Organization / Institution: Bristol-Myers Squibb Australia Pty Ltd
Author: Not specified
Target Audience: Medical professionals, Oncologists
Period of validity: Ongoing
Approval Date: 4 July 2018
Date of Changes: Not specified
Note: Contextual Description
Topics: 707 monotherapy Yervoy